Naloxone-Induced Withdrawal in Individuals With and Without Fentanyl-Positive Urine Samples

被引:7
作者
Jones, Jermaine D. [1 ,2 ]
Sherwin, Elliana [1 ,2 ]
Martinez, Suky [1 ,2 ,3 ,4 ]
Comer, Sandra D. [1 ,2 ]
机构
[1] New York State Psychiat Inst & Hosp, Div Subst Use Disorders, 1051 Riverside Dr, New York, NY 10032 USA
[2] Columbia Univ, Vagelos Coll Phys & Surg, 1051 Riverside Dr, New York, NY 10032 USA
[3] CUNY City Coll, Translat Res Training Program Addict, New York, NY 10031 USA
[4] Adelphi Univ, Gordon F Derner Sch Psychol, Garden City, NY USA
关键词
HEROIN; DEPENDENCE; SEVERITY; STATES;
D O I
10.1111/ajad.12979
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background and Objective: This retrospective analysis of data from heroin users screening for clinical research, sought to determine if more naloxone is needed to precipitate opioid withdrawal among those who regularly use heroin with fentanyl, as opposed to those who use heroin without fentanyl. Methods: Over the course of three to five screening visits, participants completed assessments of drug use, along with urine toxicology tests at each visit. To test for opioid dependence, 29 participants completed a modified Wang test (score: 0-150) during which an intramuscular dose of naloxone (0.2-0.4 mg) was administered and the severity of withdrawal was quantified. Results: The severity of opioid withdrawal was compared between individuals whose urine toxicology regularly tested positive for fentanyl (N = 15), and those only positive for other opioids (N = 14). No significant differences were found in demographic or drug use between the fentanyl-positive (mean: age 41.1 years, 9.1 bags heroin/d) and fentanyl-negative (42.0 years, 10.0 bags heroin/d) groups. Intramuscular naloxone-precipitated robust withdrawal in both samples (P <.01) with no significant difference (P =.8) in the severity (fentanyl positive [100.6 +/- 13.4]; fentanyl negative [82.7 +/- 9.6]). Conclusions and Scientific Significance: These data suggest that a standard naloxone dose can be equally effective at precipitating withdrawal in individuals using heroin with fentanyl compared to heroin without fentanyl. These data contribute to our understanding of how naloxone antagonizes the effects of fentanyl and may have significant implications for the clinical laboratory and opioid overdose. A prospective clinical laboratory study with the proper opioid maintenance controls is needed to provide a more definitive finding.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 17 条
[1]  
[Anonymous], 2017, XR NALTR STEP BY STE
[2]   Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review [J].
Armenian, Patil ;
Vo, Kathy T. ;
Barr-Walker, Jill ;
Lynch, Kara L. .
NEUROPHARMACOLOGY, 2018, 134 :121-132
[3]  
Centers for Disease Control and Prevention Health Alert Network, 2015, INCR FENT DRUG CONF
[4]  
Davis C, 2017, LEG INT RED OV MORT, P1
[5]   Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic [J].
Fairbairn, Nadia ;
Coffin, Phillip O. ;
Walley, Alexander Y. .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2017, 46 :172-179
[6]   Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths-27 States, 2013-2014 [J].
Gladden, R. Matthew ;
Martinez, Pedro ;
Seth, Puja .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2016, 65 (33) :837-843
[7]  
IBM, 2017, IBM SPSS STAT WIND V
[8]   The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety [J].
Jones, Jermaine D. ;
Bisaga, Adam ;
Metz, Verena E. ;
Manubay, Jeanne M. ;
Mogali, Shanthi ;
Ciccocioppo, Roberto ;
Madera, Gabriela ;
Doernberg, Molly ;
Comer, Sandra D. .
JOURNAL OF PSYCHOACTIVE DRUGS, 2018, 50 (05) :390-401
[9]   SEVERITY OF PRECIPITATED OPIATE WITHDRAWAL PREDICTS DRUG-DEPENDENCE BY DSM-III-R CRITERIA [J].
KOSTEN, TA ;
JACOBSEN, LK ;
KOSTEN, TR .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 1989, 15 (03) :237-250
[10]   Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device [J].
Krieter, Philip A. ;
Chiang, C. Nora ;
Gyaw, Shwe ;
McCann, David J. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08) :1078-1084